CN114377037A - Composition of lactobacillus paracasei LC-37 and application thereof in reducing blood sugar - Google Patents
Composition of lactobacillus paracasei LC-37 and application thereof in reducing blood sugar Download PDFInfo
- Publication number
- CN114377037A CN114377037A CN202210161883.9A CN202210161883A CN114377037A CN 114377037 A CN114377037 A CN 114377037A CN 202210161883 A CN202210161883 A CN 202210161883A CN 114377037 A CN114377037 A CN 114377037A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- product
- composition
- diabetes
- dietary fiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 82
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 210000004369 blood Anatomy 0.000 title claims abstract description 40
- 239000008280 blood Substances 0.000 title claims abstract description 40
- 230000001603 reducing effect Effects 0.000 title abstract description 11
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 44
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 40
- 239000008103 glucose Substances 0.000 claims abstract description 36
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 34
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 31
- 102100040918 Pro-glucagon Human genes 0.000 claims abstract description 31
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 26
- 230000001737 promoting effect Effects 0.000 claims abstract description 22
- 230000028327 secretion Effects 0.000 claims abstract description 22
- 239000006041 probiotic Substances 0.000 claims abstract description 21
- 235000018291 probiotics Nutrition 0.000 claims abstract description 21
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 13
- 210000004923 pancreatic tissue Anatomy 0.000 claims abstract description 12
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims abstract description 9
- 230000006378 damage Effects 0.000 claims abstract description 9
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 16
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 16
- 230000000529 probiotic effect Effects 0.000 claims description 15
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 235000021107 fermented food Nutrition 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 210000005027 intestinal barrier Anatomy 0.000 claims description 4
- 230000004673 intestinal mucosal barrier function Effects 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000000451 tissue damage Effects 0.000 claims description 3
- 231100000827 tissue damage Toxicity 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 21
- 241001465754 Metazoa Species 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 5
- 230000004888 barrier function Effects 0.000 abstract description 4
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 4
- 230000009467 reduction Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 208000037816 tissue injury Diseases 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 46
- 239000000047 product Substances 0.000 description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 20
- 229910052799 carbon Inorganic materials 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000016267 Leptin Human genes 0.000 description 6
- 108010092277 Leptin Proteins 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 229940039781 leptin Drugs 0.000 description 6
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 6
- 235000013618 yogurt Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 235000015140 cultured milk Nutrition 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 150000004666 short chain fatty acids Chemical class 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241001134770 Bifidobacterium animalis Species 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 229940118852 bifidobacterium animalis Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 235000021070 high sugar diet Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- -1 isomaltose oligosaccharide Chemical class 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009751 type B pancreatic cell apoptotic process Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of probiotics, in particular to a lactobacillus paracasei LC-37 composition and application thereof in blood sugar reduction. The invention discovers a new function of lactobacillus paracasei LC-37 in promoting the secretion of glucagon-like peptide 1, reducing blood sugar and relieving diabetes symptoms; the lactobacillus paracasei LC-37 is further compounded with the dietary fiber, the GLP-1 secretion promoting effect of the lactobacillus paracasei LC-37 is obviously improved, the composition of the lactobacillus paracasei LC-37 and the dietary fiber can obviously reduce the blood sugar of diabetic animals, relieve the oral glucose tolerance injury, reduce the insulin resistance index, regulate blood fat, improve the intestinal mucosa barrier and the pancreatic tissue injury, has a certain relieving effect on type II diabetes, and is safe, reliable and free of side effect.
Description
Technical Field
The invention relates to the technical field of probiotics, in particular to a lactobacillus paracasei LC-37 composition and application thereof in blood sugar reduction.
Background
Diabetes Mellitus (TDM) is a chronic metabolic disease worldwide, and world health organization data indicates that the incidence of TDM is on an increasing trend year by year in both developed and developing countries. More than 90% of TDM patients are type ii diabetes (T2D) characterized by inadequate insulin secretion and insulin resistance as well as hyperglycemia, dyslipidemia and impaired glucose tolerance. Damage to islet beta cells leads to down-regulation of insulin levels in late-mid T2D patients, and therefore additional insulin supplementation helps control blood glucose levels in T2D patients.
Glucagon-like peptide 1(GLP-1) is a hormone that is secreted primarily by intestinal L cells located in the terminal ileum and colon, and absorption of carbohydrates stimulates GLP-1 secretion. GLP-1 can promote insulin secretion and enhance beta cell sensitivity through glucose response, and gradually normalize glucose homeostasis. GLP-1 also plays an important role in controlling glucose homeostasis by stimulating insulin release from pancreatic beta cells, thereby reducing glucagon secretion from pancreatic alpha cells and suppressing appetite. In addition, GLP-1 exerts a repairing effect on pancreatic islet cells by inhibiting pancreatic beta cell apoptosis and promoting beta cell growth. At present, GLP-1 has gradually become one of the potential treatment schemes of T2D with the most promising development and application prospect.
Some probiotics have been reported to have a certain relieving effect on type II diabetes, but the research and application of probiotics, especially lactobacillus paracasei, on the GLP-1 secretion promoting effect are still very limited, so that the development of probiotics capable of better promoting GLP-1 secretion and the improvement of the efficacy of probiotics in relieving diabetes are of great significance.
Disclosure of Invention
The invention aims to provide a new application of lactobacillus paracasei LC-37; another object of the present invention is to provide a composition of Lactobacillus paracasei LC-37 and dietary fiber and uses thereof.
The Lactobacillus paracasei LC-37(Lactobacillus casei LC-37) is preserved in the common microorganism center of China Committee for culture Collection of microorganisms (address: microorganism research institute of China academy of sciences No. 3, Navy, Xilu No.1, Beijing, the rising district, 4 months and 20 days in 2017), and the preservation number is CGMCC NO. 14055. Lactobacillus paracasei LC-37 is disclosed in patent application CN 111705012A.
Lactobacillus paracasei LC-37 has functions of promoting digestion and increasing short-chain fatty acids in intestinal tract. The invention unexpectedly discovers that lactobacillus paracasei LC-37 has excellent relieving effect on diabetes, can obviously promote the secretion of glucagon-like peptide 1, obviously reduce blood sugar, relieve oral glucose tolerance damage and improve insulin resistance, has obvious improving effect on intestinal mucosa barrier and pancreatic tissue damage caused by diabetes, and can be used for auxiliary prevention or treatment of diabetes.
Specifically, the invention provides the following technical scheme:
the invention provides application of lactobacillus paracasei LC-37 or a culture thereof in preparing a product for promoting secretion of glucagon-like peptide 1;
and the use of Lactobacillus paracasei LC-37 or a culture thereof for the preparation of a product for the amelioration, prevention or treatment of diabetes;
and the use of Lactobacillus paracasei LC-37 or a culture thereof for the preparation of a product for lowering blood glucose;
and the use of Lactobacillus paracasei LC-37 or a culture thereof for the preparation of a product for improving insulin resistance;
and the use of Lactobacillus paracasei LC-37 or a culture thereof for the preparation of a product for improving the intestinal mucosal barrier or pancreatic tissue damage caused by diabetes.
In the above-described applications, the culture of Lactobacillus paracasei LC-37 may comprise Lactobacillus paracasei LC-37 and a cell-free culture supernatant obtained by culturing Lactobacillus paracasei LC-37, or may comprise only a cell-free culture supernatant obtained by culturing Lactobacillus paracasei LC-37.
In the above applications, the product is a food or a medicament, including but not limited to a probiotic product or a fermented food, wherein the probiotic product includes but not limited to a probiotic powder, a probiotic tablet, a probiotic capsule/soft capsule; fermented food products include, but are not limited to, fermented milks, fermented milk powders, yogurt nuggets, yogurt powders, yogurt, cheese.
In the above-mentioned use, the diabetes is preferably type II diabetes.
In the application, the viable bacteria concentration of the lactobacillus paracasei LC-37 in the product is more than or equal to 5 multiplied by 108CFU/mL (liquid product, preferably 5X 10)8～5×1010CFU/mL), or ≧ 1X 106CFU/g (solid product, preferably 1X 10)6～1×108CFU/g)。
On the basis of lactobacillus paracasei LC-37, the present invention provides a composition comprising dietary fiber and a culture of lactobacillus paracasei LC-37 and/or lactobacillus paracasei LC-37.
Preferably, the dietary fiber is one or more of galacto-oligosaccharide, isomalto-oligosaccharide, xylo-oligosaccharide and pectin.
Further preferably, the dietary fiber is isomaltooligosaccharide or galactooligosaccharide.
Compared with other dietary fibers, the lactobacillus paracasei LC-37 is combined with isomaltose hypgather or galacto-oligosaccharide, and the isomaltose hypgather or the galacto-oligosaccharide can provide a carbon source and an energy source for the growth of the lactobacillus paracasei LC-37, specifically promote the growth of the lactobacillus paracasei LC-37, simultaneously promote the lactobacillus paracasei LC-37 to play a role in promoting the secretion of glucagon-like peptide 1, and obviously improve the remission effect of the lactobacillus paracasei LC-37 on type II diabetes.
In the composition, the concentration of Lactobacillus paracasei LC-37 is 5 × 108～5×1010CFU/mL, the mass concentration of the dietary fiber is 0.75-3% (g: mL). The lactobacillus paracasei LC-37 and the dietary fiber (especially isomaltooligosaccharide or galactooligosaccharide) are combined and used according to the proportion, so that the coordination of the lactobacillus paracasei LC-37 and the dietary fiber can be better promoted, and the glucagon-like peptide 1 secretion promoting and blood sugar reducing effects of the composition can be favorably improved.
Based on the function of the composition, the invention provides any one of the following uses of the composition:
(1) the use in the preparation of a product for promoting the secretion of glucagon-like peptide 1;
(2) the application of the compound in preparing products for improving, preventing or treating diabetes;
(3) the use in the manufacture of a product for lowering blood glucose;
(4) use in the manufacture of a product for improving insulin resistance;
(5) the use in the manufacture of a product for ameliorating damage to the intestinal mucosal barrier or pancreatic tissue resulting from diabetes;
(6) the application in preparing probiotic products or fermented food.
In the above-mentioned application, the product is a food or a medicament. The diabetes is preferably type II diabetes.
The invention provides a product which is a probiotic product containing the composition, or a fermented food containing the composition.
Such probiotic products include, but are not limited to, probiotic powders, probiotic tablets, probiotic capsules/softgels; fermented food products include, but are not limited to, fermented milks, fermented milk powders, yogurt nuggets, yogurt powders, yogurt, cheese.
Preferably, the product is a drug or food for reducing blood sugar or improving diabetes.
The beneficial effects of the invention at least comprise: the invention discovers a new function of lactobacillus paracasei LC-37 in promoting the secretion of glucagon-like peptide 1, reducing blood sugar and relieving diabetes symptoms; the lactobacillus paracasei LC-37 and the dietary fiber are further compounded, and in-vitro cell experiments and animal experiments prove that the composition of the lactobacillus paracasei LC-37 and the dietary fiber can obviously improve the GLP-1 secretion promoting effect of the lactobacillus paracasei LC-37, reduce the blood sugar of diabetic animals, relieve the oral glucose tolerance injury, reduce the insulin resistance index, regulate the blood fat, improve the intestinal mucosa barrier and the pancreatic tissue injury, has a certain relieving effect on type II diabetes, and is safe, reliable and free of side effects.
Drawings
FIG. 1 shows the case where Lactobacillus paracasei LC-37 promotes GLP-1 secretion from cells in example 1 of the present invention.
FIG. 2 shows the growth of Lactobacillus paracasei LC-37 with different dietary fibers as carbon sources in example 2 of the present invention.
FIG. 3 shows the growth of Lactobacillus paracasei LC-37 cultured with different concentrations of dietary fiber as a carbon source in example 2 of the present invention.
FIG. 4 shows the GLP-1 secretion of cells promoted by Lactobacillus paracasei LC-37 and dietary fibers at different doses in example 3 of the present invention.
FIG. 5 is a graph showing the concentration of short chain fatty acids in the fermentation broth of different dietary fiber and Lactobacillus paracasei compositions of example 3 of the present invention.
FIG. 6 shows fasting plasma glucose levels of different groups of T2D rats before and after intervention in example 4 of the present invention.
FIG. 7 is the area under the oral glucose tolerance line before and after intervention in different groups of T2D rats in example 4 of the present invention.
FIG. 8 is a graph showing the serum insulin and leptin levels of different groups of T2D rats in example 4 of the present invention, wherein A is the insulin level and B is the leptin level.
FIG. 9 shows the HOMA-IR profiles of different groups of T2D rats in example 4 of the present invention.
FIG. 10 is a graph showing the blood lipids of different groups of T2D rats in example 4 of the present invention.
FIG. 11 shows colon histology of different groups of T2D rats in example 4 of the present invention.
FIG. 12 is a staining of pancreatic tissue sections of different groups of T2D rats in example 4 of the present invention.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
The dietary fibres referred to in the following examples are shown in table 1 below:
TABLE 1 dietary fiber
The media used in the following examples were prepared as follows:
MRS medium (1L): 10g of peptone, 5g of yeast extract powder, 20g of glucose, 10g of beef extract and K2HPO42g of diammonium citrate, 2g of MgSO4〃7H2O 0.58g，MnSO4〃4H20.25g of O, 5g of anhydrous sodium acetate, 801 mL of Tween, 0.5g of cysteine hydrochloride, and distilled water to a constant volume of 1L, adjusting the pH value to 6.5, and sterilizing at 121 ℃ for 15 min.
The culture medium is selected as a basic culture medium and is used as a blank control group, the experimental group replaces glucose with dietary fiber on the basis, and the carbon-source-free culture medium is used as a negative control.
Example 1 Lactobacillus paracasei LC-37 promotes secretion of GLP-1 by cells
NCI-H716 cells at 1.5X 106The density of each well is planted in a 12-well plate coated with matrigel, cultured for 2d, and subjected to endocrine differentiation experiments. The medium used for endocrine differentiation was high-glucose DMEM medium containing 10% fetal bovine serum and 1% diabody. After 2 days, DMEM medium was treated with KRB buffer (128.8mmol/L NaCl, 4.8mmol/L KCl, 1.2mmol/L KH)2PO4，1.2mmol/L MgSO4，2.5mmol/L CaCl2，5mmol/LNaHCO3And 10mmol/L HEPES, pH 7.4), and (i) a concentration of 5X 10 is added to each buffer solution8CFU/mL of different lactic acid bacteria strains at a concentration of 5X 10%10CFU/mL of different lactic acid bacteria strains, ③ strain fermentation liquor (thallus-free supernatant of culture solution) sampled in the stabilization period,each group of three parallel, at 37 deg.C and 5% CO2After 2h of culture in an incubator, centrifuging for 10min under the condition of 1000 Xg, and detecting the GLP-1 content in cell supernatant. The supernatant was added with 50. mu.g/mL of phenylmethylsulfonyl fluoride (PMSF) and 10. mu.g/mL of DPP-4 inhibitor, and then the concentration of GLP-1 was measured by ELISA kit. The GLP-1 secretion promoting effect of lactobacillus paracasei LC-37 is compared by using Bifidobacterium animalis ssp.420 as a positive control strain.
The results are shown in FIG. 1, in which the low dose group concentration is 5X 108CFU/mL, high dose group concentration of 5X 1010CFU/mL. Compared with the bifidobacterium animalis B420, the overall effect of the lactobacillus paracasei LC-37 on promoting NCI-H716 cells to secrete GLP-1 is better than that of the bifidobacterium animalis B420, especially the LC-37 high-dose group (p)<0.05), which shows that the lactobacillus paracasei LC-37 has the effect of promoting GLP-1 secretion and has potential application possibility of relieving the symptoms of type II diabetes.
EXAMPLE 2 development of Lactobacillus paracasei-dietary fiber composition
1. Screening dietary fiber compounded with lactobacillus paracasei LC-37
The final concentration of each dietary fiber in table 1 was adjusted to 1.5%, the initial pH was adjusted to 6.5, and after sterilization treatment, 1% of activated lactobacillus paracasei LC-37 was aspirated, inoculated into MRS medium (dietary fiber as a carbon source), MRS medium (glucose as a carbon source), and carbon source-free medium, and subjected to static culture at 37 ℃. And measuring the absorbance of the fermentation liquor at 660nm when the fermentation liquor is cultured for 0h, 4h, 8h, 12h and 24h respectively, and tracking and inspecting the growth condition of the strain. And calculating a Probiotic Index (PI), and selecting 3-5 dietary fibers with the best stimulation to the growth of the lactobacillus paracasei LC-37 strain, wherein the calculation formula of the PI is as follows:
PI＝[(APP24-APP0)-(APN24-APN0)]/[(APG24-APG0)-(APN24-APN0)]；
wherein A isPP24And APP0Respectively the absorbance of the strain when the carbon source of the culture medium is dietary fiber for 24h and 0h, APG24And APG0Respectively, the carbon source of the strain in the culture medium is grapeAbsorbance for 24h and 0h in sugar; a. thePN24And APN0The absorbance of the strain cultured in carbon-source-free MRS medium for 24h and 0h respectively.
The dietary fibers that were screened in preliminary experiments and could be fully solubilized and formulated as carbon sources into liquid media are shown in table 2:
table 2 screening dietary fiber list
The dietary fibers are used as carbon sources to prepare a culture medium, and lactobacillus paracasei LC-37 is cultured, the results are shown in figure 2, the growth conditions of the LC-37 in the culture medium taking different dietary fibers as carbon sources are different, wherein the carbon sources with good effect of promoting the growth of the lactobacillus paracasei LC-37 are galacto-oligosaccharide, isomalto-oligosaccharide, xylo-oligosaccharide and pectin, and therefore the four carbon sources are selected for the next experiment.
2. Screening for dietary fiber concentration
Adopting the dietary fiber screened in the step 1, adjusting the concentration of the dietary fiber to be 0.75%, 1.5% and 3%, adjusting the initial pH to be 6.5, after sterilization treatment, absorbing 1% of activated lactobacillus paracasei LC-37, respectively inoculating the activated lactobacillus paracasei LC-37 into the fermentation medium (the dietary fiber is used as a carbon source), the MRS basic medium (glucose is used as a carbon source) and the carbon-source-free medium, and standing and culturing at 37 ℃. And measuring the absorbance of the fermentation liquor at 660nm when the fermentation liquor is cultured for 0h, 4h, 8h, 12h and 24h respectively, and tracking and inspecting the growth condition of the strain. And calculating a Probiotic Index (PI) and selecting the concentration of the dietary fiber which best stimulates the growth of the strain.
As shown in FIG. 3, the dietary fiber having the best growth promoting effect on Lactobacillus paracasei LC-37 and the concentrations of 1.5% galacto-oligosaccharide (3% galacto-oligosaccharide has no significant difference in growth promoting effect from 1.5% galacto-oligosaccharide) and 1.5% isomalto-oligosaccharide were obtained. The 3% pectin as carbon source medium did not dissolve completely and therefore did not provide this result.
EXAMPLE 3 in vitro experiment of Lactobacillus paracasei-dietary fiber compositions
The two compositions of lactobacillus paracasei LC-37+ 1.5% galacto-oligosaccharide and lactobacillus paracasei LC-37+ 1.5% isomalto-oligosaccharide obtained by screening in example 2 were subjected to in vitro experiments, specifically as follows:
1. GLP-1 secretion promoting effect
NCI-H716 cells at 1.5X 106The density of each well is planted in a 12-well plate coated with matrigel, cultured for 2d, and subjected to endocrine differentiation experiments. The medium used for endocrine differentiation was high-glucose DMEM medium containing 10% fetal bovine serum and 1% diabody. After 2 days, DMEM medium was treated with KRB buffer (128.8mmol/L NaCl, 4.8mmol/L KCl, 1.2mmol/L KH)2PO4，1.2mmol/L MgSO4，2.5mmol/L CaCl2，5mmol/LNaHCO3And 10mmol/L HEPES, pH 7.4), adding Lactobacillus paracasei LC-37 with dietary fiber as carbon source and Lactobacillus paracasei LC-37 fermentation liquor with dietary fiber as carbon source into buffer solution, wherein each group of three fermentation liquor is parallel, placing at 37 deg.C and 5% CO2After 2h of culture in an incubator, centrifuging for 10min under the condition of 1000 Xg, and detecting the content of GLP-1 in cell supernatant by an ELISA kit method.
The results are shown in FIG. 4, in which the concentration of Lactobacillus paracasei LC-37 was 5X 1010CFU/mL, dietary fiber in the composition was 1.5% galacto-oligosaccharide or 1.5% isomalto-oligosaccharide, respectively. The composition of lactobacillus paracasei LC-37 and isomaltooligosaccharide or galactooligosaccharide can obviously improve the concentration of GLP-1 secretion of cells.
2. Determination of short-chain fatty acid content
The concentration of short chain fatty acids (including acetic acid and propionic acid) in the fermentation broth of lactobacillus paracasei LC-37 using different dietary fibers as carbon sources was determined by gas chromatography with PBS (control group) and bifidobacterium lactis B420 in the fermentation broth using glucose as carbon source as control.
As shown in FIG. 5, 1.5% galacto-oligosaccharide and 1.5% isomaltose oligosaccharide were both fermented by Lactobacillus paracasei LC-37, which significantly increased the acetic acid content of the fermentation broth, but no significant difference was observed between the propionic acid content groups.
Example 4 animal experiments with Lactobacillus paracasei-dietary fiber compositions
Adult male Wistar rats (150 +/-20 g) are taken as experimental objects, a type II diabetes mellitus (T2D) model is established by utilizing high-fat feed and Streptozotocin (STZ) induction, and the relieving effect of the lactobacillus paracasei LC-37-dietary fiber composition on T2D is researched.
After purchasing healthy rats, after adaptive feeding of 1w, the groups were randomly divided into two groups, and the control group and the model group were subjected to high-sugar and high-fat diet induction of 4w before STZ induction. During the experiment, the control group is fed with basal feed, the model group is fed with high-fat feed, all experimental rats are given free drinking water and free ingestion, and the weight, the fasting blood sugar and the postprandial blood sugar are measured once a week.
After the induction of high-sugar and high-fat diet for 4w, the rats were fasted without water deprivation for 12h, the body weight of the rats was measured, and the rats in the model group were subjected to STZ intraperitoneal injection at 30mg/kg · bw. Normal group rats were injected with equal amounts of buffer. After 1w of injection, determining the fasting blood sugar of the rat, and judging whether the molding is successful or not by taking the fasting blood sugar not less than 11.1mmol/L as a standard. The rats successfully modeled were randomly divided into 5 groups of 8 rats per group based on fasting blood glucose. According to the grouping (table 3), lactobacillus paracasei LC-37-dietary fiber composition was gavaged, 7 w.
TABLE 3 animal Experimental groups
The measurement items include blood sugar and sugar tolerance, biochemical indexes, serum GLP-1 content, and the influence on intestinal permeability and islet injury.
1. Blood glucose and glucose tolerance test
(1) Basic index determination
Rat weight changes, including percent weight gain and change in food intake, were measured once a week.
(2) Determination of biochemical indices
Detection of glycosylated hemoglobin, leptin, insulin and fasting plasma glucose; the insulin resistance index (HOMA-IR) is calculated according to the formula:
(3) oral Glucose Tolerance Test (OGTT)
Oral glucose tolerance was determined one week after modeling and one week before sacrifice for all rats. After the rats are fasted for 16 hours without water prohibition, 2g/kg & bw of glucose aqueous solution (prepared according to the g/mL of 40%) is perfused, and then tail vein blood of the rats is taken at 0min, 30min, 60min, 90min and 120min respectively, and the blood glucose value is measured and recorded by a glucometer and matched blood glucose test paper. After blood sampling, the punctured site of the rat was wiped with iodophor to prevent infection. Drawing a blood glucose change curve by using Orgin 9.0 software according to the blood glucose value and calculating the area under the glucose tolerance curve (AUC)glu) The AUC value directly reflects the glucose tolerance of the rat.
2. Determination of biochemical indices
Rat blood lipid levels, including changes in serum Triacylglycerols (TG), Total Cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), were determined using a fully automated biochemical analyzer.
3. Effects on intestinal permeability and islet injury
Colonic epithelial mucosal barrier: pathological sections of rat colonic epithelial mucosa are observed mainly after HE staining;
pathological observation of islet lesions: pathological sections of rat pancreatic tissue were observed mainly after HE staining.
The detection results of the above indexes are as follows:
after STZ intervention, the weight of the diabetes model group is obviously reduced, the fasting blood glucose value of the control group is 4.29 +/-0.33 mmol/L, the fasting blood glucose value of the model group is respectively 16.98 +/-3.93 mmol/L, 16.91 +/-1.50 mmol/L, 16.21 +/-2.21 mmol/L and 16.80 +/-2.18 mmol/L, which are all more than 11.1mmol/L, which indicates that the diabetes model molding is successful after the gavage of 7 w.
The fasting blood glucose values of rats in each group are shown in fig. 6, the fasting blood glucose value of the model group is significantly higher than that of the control group (p <0.05), the fasting blood glucose of the T2D rats is significantly reduced after intervention (p <0.05), and the reduction effect of the lactobacillus paracasei LC-37 and the dietary fiber composition is not significantly different from that of the drug group.
The area under the oral glucose tolerance line of each group of rats is shown in fig. 7. After STZ induction, the OGTT of the diabetic rats is damaged, but each intervention group can relieve T2D rats from being damaged continuously to a certain extent, wherein the composition 1 has a remarkable improving effect (p <0.05) on the OGTT.
The insulin and leptin levels of rats in each group are shown in fig. 8, the serum insulin and leptin of rats in the model group are not significantly different from those in the control group, and the serum insulin and leptin of rats in each intervention group are also not significantly different from those in the model group.
The insulin resistance levels of the rats in each group are shown in fig. 9, the insulin resistance index of the model group is significantly increased (p <0.05) compared with that of the control group, the insulin resistance index of the drug group, the composition 1 group and the composition 2 group is significantly reduced (p <0.05) compared with that of the model group, and the effect of the two groups of lactobacillus paracasei LC-37 composition dried groups is not significantly different from that of the drug group.
The four biochemical indicators of the rat blood are shown in fig. 10, the content of Triglyceride (TC) in the rat blood serum of the model group is obviously increased (p is less than 0.05) compared with the control group, but the effect of reducing triglyceride of the intervention group is not obvious.
The content of total cholesterol (TG) in the serum of rats in the model group is obviously higher than that in the control group (p is less than 0.05), and the effect of reducing the total cholesterol by lactobacillus paracasei LC-37 and the dietary fiber composition intervention group (composition 1 and composition 2) is obvious (p is less than 0.05), and the effect is not obvious different from that of the drug group.
The intervention of the lactobacillus paracasei LC-37 and dietary fiber composition can obviously improve the content of high-density lipoprotein (HDL-C) in the serum of a T2D rat, and simultaneously reduce the content of low-density lipoprotein (LDL-C) in the serum of the rat (p < 0.05).
Pathological observation of colonic epithelial mucosa:
histology of rat colon is shown in fig. 11, and in the control group, epithelial and mucosal structures are intact without inflammatory infiltration. In the diabetes model group, epithelial integrity was impaired, part of the cells were damaged, detachment from the mucosal surface, and smooth muscle was thinned and exfoliated. Intervention of the lactobacillus paracasei LC-37 composition can normalize the epithelium and mucosal structure of diabetic rats, the mucosa is more intact, goblet cells are increased, and epithelial cell shedding is reduced.
Pathological observation of pancreatic tissue:
rat pancreatic tissue section staining As shown in FIG. 12, islet cells of the normal control group rat are circular or elliptical and have clear cellular characteristics, islet cell volume of the model group rat is reduced, cell structure is irregular, cell morphology is incomplete, and the intervention of the Lactobacillus paracasei LC-37 composition can significantly improve islet cell volume of the rat.
In conclusion, the best combination for promoting NCIH-716 to secrete GLP-1 is screened to be 5 × 10 by in vitro cell experiments10Combination of CFU/mL Lactobacillus paracasei LC-37 and 1.5% isomaltooligosaccharide or 1.5% galacto-oligosaccharide. Secondly, the relieving effect of the lactobacillus paracasei-dietary fiber composition on diabetes is evaluated by utilizing a type II diabetes rat model, and the composition is determined to be capable of reducing the blood sugar of the diabetes rat, relieving the oral glucose tolerance injury, reducing the insulin resistance index, regulating blood fat, improving the intestinal mucosa barrier and the pancreatic tissue injury, and has an obvious relieving effect on type II diabetes.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (10)
1. Use of lactobacillus paracasei LC-37 or a culture thereof for the preparation of a product for promoting the secretion of glucagon-like peptide 1.
2. Use of lactobacillus paracasei LC-37 or a culture thereof for the preparation of a product for the amelioration, prevention or treatment of diabetes.
3. Use of lactobacillus paracasei LC-37 or a culture thereof for the preparation of a product for lowering blood glucose.
4. Use of lactobacillus paracasei LC-37 or a culture thereof for the preparation of a product for improving insulin resistance.
5. Use of lactobacillus paracasei LC-37 or a culture thereof for the preparation of a product for improving the intestinal mucosal barrier or pancreatic tissue damage caused by diabetes.
6. A composition comprising dietary fibre and a culture of lactobacillus paracasei LC-37 and/or lactobacillus paracasei LC-37.
7. The composition according to claim 6, wherein the dietary fiber is selected from one or more of galacto-oligosaccharide, isomalto-oligosaccharide, xylo-oligosaccharide and pectin; preferably isomaltooligosaccharides or galactooligosaccharides.
8. The composition according to claim 6 or 7, wherein the concentration of Lactobacillus paracasei LC-37 in the composition is 5 x 108～5×1010CFU/mL, the mass concentration of the dietary fiber is 0.75-3%.
9. Use of the composition of any one of claims 6 to 8 in any one of the following applications:
(1) the use in the preparation of a product for promoting the secretion of glucagon-like peptide 1;
(2) the application of the compound in preparing products for improving, preventing or treating diabetes;
(3) the use in the manufacture of a product for lowering blood glucose;
(4) use in the manufacture of a product for improving insulin resistance;
(5) the use in the manufacture of a product for ameliorating damage to the intestinal mucosal barrier or pancreatic tissue resulting from diabetes;
(6) the application in preparing probiotic products or fermented food.
10. A product, characterized in that it is a probiotic product comprising a composition according to any one of claims 6 to 8, or alternatively it is a fermented food product comprising a composition according to any one of claims 6 to 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210161883.9A CN114377037A (en) | 2022-02-22 | 2022-02-22 | Composition of lactobacillus paracasei LC-37 and application thereof in reducing blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210161883.9A CN114377037A (en) | 2022-02-22 | 2022-02-22 | Composition of lactobacillus paracasei LC-37 and application thereof in reducing blood sugar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114377037A true CN114377037A (en) | 2022-04-22 |
Family
ID=81205756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210161883.9A Pending CN114377037A (en) | 2022-02-22 | 2022-02-22 | Composition of lactobacillus paracasei LC-37 and application thereof in reducing blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114377037A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114350547A (en) * | 2021-12-17 | 2022-04-15 | 四川省医学科学院·四川省人民医院 | Bifidobacterium lactis strain B-622 and application thereof in preparation of medicines for treating diabetes |
| CN115300531A (en) * | 2022-09-02 | 2022-11-08 | 东北农业大学 | Lactobacillus paracasei JY062 composition and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111705012A (en) * | 2020-05-22 | 2020-09-25 | 内蒙古蒙牛乳业（集团）股份有限公司 | Lactobacillus paracasei LC-37 with digestion promoting effect and application thereof |
-
2022
- 2022-02-22 CN CN202210161883.9A patent/CN114377037A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111705012A (en) * | 2020-05-22 | 2020-09-25 | 内蒙古蒙牛乳业（集团）股份有限公司 | Lactobacillus paracasei LC-37 with digestion promoting effect and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| JIAYUAN ZHAO等: "A Potential Synbiotic Strategy for the Prevention of Type 2 Diabetes: Lactobacillus paracasei JY062 and Exopolysaccharide Isolated from Lactobacillus plantarum JY039", 《NUTRIENTS》, vol. 17, no. 377, pages 7 - 8 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114350547A (en) * | 2021-12-17 | 2022-04-15 | 四川省医学科学院·四川省人民医院 | Bifidobacterium lactis strain B-622 and application thereof in preparation of medicines for treating diabetes |
| CN114350547B (en) * | 2021-12-17 | 2023-05-16 | 四川省医学科学院·四川省人民医院 | Bifidobacterium lactis strain B-622 and application thereof in preparation of medicines for treating diabetes |
| CN115300531A (en) * | 2022-09-02 | 2022-11-08 | 东北农业大学 | Lactobacillus paracasei JY062 composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11291697B2 (en) | Probiotic composition and use thereof | |
| CN109628358B (en) | Composite probiotics and application thereof | |
| CN114377037A (en) | Composition of lactobacillus paracasei LC-37 and application thereof in reducing blood sugar | |
| CN112244299B (en) | Probiotic composition with function of relieving nonalcoholic fatty liver and preparation method thereof | |
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| TWI770746B (en) | Lactobacillus fermentum strain and composition for preventing or treating metabolic disease including the same | |
| CN116042477B (en) | Lactobacillus plantarum J26 composition, preparation method and application thereof in weight-losing products | |
| CN111164201B (en) | Lactobacillus paracasei GKS6 for improving metabolic syndrome, use thereof, pharmaceutical composition and edible composition | |
| CN115381860B (en) | Composition for protecting alcoholic liver injury and preparation method and application thereof | |
| CN112586744A (en) | Probiotic tablet capable of controlling body weight and preparation method thereof | |
| CN117264829A (en) | Lactobacillus plantarum for preventing and treating hypercholesterolemia, fermented product and application thereof | |
| CN112535700A (en) | Weight-losing powder based on lactobacillus and preparation method thereof | |
| CN117778279B (en) | Probiotic agent for degrading ethanol and application thereof | |
| KR101407980B1 (en) | Products containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 having improving hyperinsulinemia, hyperglycemia and hypertriglyceridemia as effective component | |
| CN111304134B (en) | Lactobacillus plantarum capable of effectively relieving diabetes | |
| CN111867402A (en) | Agaricus campestris composite mycelium composition with liver function improving activity and its preparation method | |
| CN114617265A (en) | Application of inactivated lactobacillus casei IOB-P9 metagenesis powder in reducing blood sugar | |
| CN113116941A (en) | Probiotics and prebiotics compound preparation capable of relieving type 2 diabetes and preparation method thereof | |
| CN117547029B (en) | Lactobacillus plantarum J26 metazoan freeze-dried powder with weight-losing and lipid-lowering effects, and preparation method and application thereof | |
| CN115386518B (en) | Lactobacillus rhamnosus strain with D-psicose as carbon source, and derivative product and application thereof | |
| CN117363524B (en) | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines | |
| CN117384790B (en) | Pediococcus pentosaceus KS5 and application thereof in preparation of sleep-aiding drugs | |
| CN112538440B (en) | Compound probiotic preparation, preparation method thereof and application of compound probiotic preparation in promotion of ethanol metabolism of human body | |
| CN116396891B (en) | Probiotic composition of lactobacillus acidophilus LA-G80 and bifidobacterium bifidum BB-G90 and application thereof in liver protection | |
| CN117384788B (en) | Saliva combined lactobacillus SM4 and application thereof in preparation of whitening and cholesterol lowering foods and medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |